2025 AHA/ACC Multi-Society Hypertension Guideline Redefines Risk and Treatment Thresholds

The 2025 AHA/ACC Guideline introduces PREVENT-based CVD risk, new secondary hypertension triggers, and major changes in initial drug therapy for pharmacists managing hypertension.

2025 AHA/ACC hypertension guidelinehypertensionPREVENT riskantihypertensive drug classessingle-pill combinationaldosteronismHBPM Hypertension

Authors: Writing Committee Members*, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP, Carter J, Cohen JB, Collins KJ, Commodore-Mensah Y, Davis LL, Egan B, Khan SS, Lloyd-Jones DM, Melnyk BM, Mistry EA, Ogunniyi MO, Schott SL, Smith SC Jr, Talbot AW, Vongpatanasin W, Watson KE, Whelton PK, Williamson JD

Citation: Writing Committee Members*, Jones DW, Ferdinand KC, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2025;82(10):e212-e316. doi:10.1161/HYP.0000000000000249

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Practice-changing Impact 3/5

The adoption of PREVENT risk, universal aldosteronism screening in resistant hypertension, and required initial single-pill combinations for stage 2 hypertension are practice-altering for pharmacists.

Evidence Grade: Moderate

Most recommendations are supported by RCTs and meta-analyses (Level A or B evidence), but some apply limited US- or disease-specific evidence or extrapolate from international or observational sources.

What's New / Changed vs. Prior Version

The 2025 guideline introduces revised blood pressure thresholds, new treatment algorithms, expanded guidance on home BP monitoring, and updates to pharmacotherapy for resistant hypertension and special populations (CKD, diabetes, pregnancy). This retires the 2017 ACC/AHA Guideline.

Key Recommendations

For adults with confirmed hypertension and CVD or increased ASCVD risk, initiate lifestyle modifications and pharmacotherapy aiming for a target of <130/80 mm Hg (Class I, Level of Evidence A). For patients with resistant hypertension, an additional antihypertensive agent from a different class should be considered (Class I, Level of Evidence B). Special considerations for CKD patients emphasize ACE inhibitors or angiotensin receptor blockers (ARBs) as initial therapy (Class I, Level of Evidence A).

Practice Impact for Pharmacists

Pharmacists need to familiarize themselves with the revised blood pressure thresholds for treatment initiation and goals.
Increased focus on patient education regarding accurate home blood pressure monitoring.
Expand pharmacotherapy for resistant hypertension by ensuring access to diverse antihypertensive classes.

Implementation Considerations

Key barriers include the cost and access to newer antihypertensive classes, need for systems to integrate home BP monitoring data into electronic health records, and training for healthcare professionals on updated treatment algorithms.

Controversies / Dissenting Opinions

None noted.

Full text source: Drive Upload – GL – Hypertension – 2025 AHA ACC Guideline for the Prevention Detection and Management of High Blood Pressure.pdf (OpenAI Vision)